A New CDK4/6 Inhibitor in Breast Cancer: Significantly Longer Survival with Tibremciclib

Tibremciclib in Advanced Breast Cancer: How Strong Is the Benefit–Risk Balance? Phase 3 TIFFANY Results

The new-generation CDK4/6 inhibitor tibremciclib (Betta Pharmaceuticals), when added to second-line fulvestrant treatment in patients with HR-positive/HER2-negative advanced breast cancer , significantly prolonged progression-free survival (PFS) . However, this gain came with an increased risk of toxicity .

 The Phase 3 TIFFANY trial results show that, compared with fulvestrant alone, the tibremciclib combination extended median PFS by 11 months. However, treatment-related diarrhea, hematologic toxicities and hypokalemia were markedly more frequent.

Study Design and Participants

A total of 274 patients from 69 centers in China had progressed during endocrine therapy and received no more than 1 line of chemotherapy.

Randomization: At a 2:1 ratio

• Tibremciclib + Fulvestrant (400 mg orally, 1 time daily)
• Placebo + Fulvestrant

Treatment continued until disease progression, death or treatment discontinuation .

Median follow-up: 13 months

Main Findings

Median PFS: Tibremciclib group: 16.5 months

• Fulvestrant group: 5.6 months
• Progression risk showed a 63% reduction (HR, 0.37; P < .001) 

Toxicity rates were higher, but the rate of permanent treatment discontinuation was low (only 4 patients).

Adverse-Effect Profile

Most common treatment-related adverse effects (tibremciclib vs placebo):

• Diarrhea: 79.3% vs 13.3%
• Neutropenia: 75.5% vs 15.6%
• Leukopenia: 73.9% vs 16.7%
• Anemia: 69% vs 21.1%
• Nausea: 37% vs 18.9%
• Vomiting: 40.2% vs 11.1%

Grade 3+ adverse effects occurred in the tibremciclib arm in 50.5%, and in the placebo arm in 21.1% of patients.

Most common serious adverse effects: neutropenia (15.2%), anemia (12.0%), hypokalemia (12.0%).

Most hypokalemia cases were due to diarrhea and managed with electrolyte monitoring + potassium supplementation .

Comparison with Other CDK4/6 Inhibitors

The toxicity profile was similar to that of ribociclib and palbociclib . Neutropenia and leukopenia rates, compared with abemaciclib, dalpiciclib and palbociclib trials, were lower . Tibremciclib’s high selectivity for CDK4 , with less CDK6 and CDK9 inhibition, may reduce severe diarrhea and neutropenia rates.

The PFS gain was higher than with some other CDK4/6 inhibitors:

• Palbociclib (PALOMA-3): 9.5 months vs 4.6 months (HR, 0.46)
• Abemaciclib (MONARCH): 11.5 months vs 5.6 months (HR, 0.38)
• Dalpiciclib (DAWNA-1): 16.6 months vs 7.2 months (HR, 0.50)

Clinical Significance and Limitations

• Tibremciclib + fulvestranthas received approval in China for HR-positive/HER2-negative advanced breast cancer .
• Not yet approved in the US or Europe.
• The study was conducted only in Chinese patients and was limited to patients who had not previously received a CDK4/6 inhibitor .

Therefore, generalizability may be limited, particularly in Western countries.

Conclusion

Tibremciclib + fulvestrant stands out as a potent option that, in advanced HR-positive/HER2-negative breast cancer, significantly prolongs PFS and has a manageable adverse-effect profile . The benefit–risk balance appears favorable, although efficacy in broader populations and average survival data are awaited.